President’s Research Fund (PRF)
The President’s Research Fund (PRF) supports projects that have a strong potential for obtaining external funding for SLU investigators. Funds are used to collect preliminary data that will generate new extramural funding.
Specifically, the PRF will:
- Incentivize new research of high scientific quality that is likely to secure extramural funding.
- Support existing research reviewed favorably by the NIH but not yet funded.
The RPC will administer a single PRF cycle for the School of Medicine (SOM) during FY18 (Cycle 15), with a deadline of January 16, 2018, and a start date of April 2, 2018.
The following three types of applications will be considered for funding:
- PRF01 – Single PI application describing a NEW project with high likelihood of extramural funding, preferably through the R01 or U01 mechanisms. Up to $50,000 may be requested for this award.
- PRF02 – Multi-PI application describing a NEW project with high likelihood of extramural funding, preferably through the P01 mechanism. Up to $100,000 may be requested for this award.
- PRF03 – Existing R01 or U01 application, NEW or RENEWAL, that was scored but not funded by the NIH during 2017. Up to $50,000 may be requested for this award.
Guidelines and Application for Cycle 15:
- Cycle 15 Guidelines: PRF Guidelines
- Cycle 15 Application: PRF Application
- Cycle 15 Subrecipient Form: PRF Subrecipient
Applicants should include a cover letter that justifies submission of the PRF01 or PRF02 as a NEW research project. For PRF03 grants, applicants should include a copy of the original R01 or U01 grant proposal reviewed by the NIH, a copy of the summary statement, and a description, not to exceed 5 pages, of how criticisms raised by the NIH Study Section will be addressed in a revised application.
The application deadline is January 16, 2018 and no late applications will be considered. Applications must be submitted online through eRS as an Internal Proposal. Proposals must be electronically signed by the PI’s department-appointed approver by 5:00 p.m. CST.
All applications (PRF01s, PRF02s and PRF03s) will be reviewed by an Internal Study Section appointed by the RPC and chaired by the current chair of the RPC. Recommendations about funding and amounts to be awarded rest entirely with the Internal Study Section and will be based on scientific merit and likelihood of extramural funding. These recommendations will be forwarded to the Vice President of Research for final approval.
Questions about Cycle 15 of the PRF in the SOM should be directed to Denise Johnson (977-8067; email@example.com).
Example of a successful PRF application: Tavis PRF
Award recipients for the 2017 Cycle 14 applications are listed below.
|Yuna Ayala, Ph.D.||Biochemistry and Molecular Biology||“Cellular model to detect propagation of TDP-43 aggregates in neurodegeneration”|
|Ángel Baldán, Ph.D.||Biochemistry and Molecular Biology||“The role of CIDEC/FSP27 on lipid metabolism in health and disease”|
|James Brien, Ph.D.||Molecular Microbiology and Immunology||“Antibody based therapeutics for zika virus”|
|Sandeep Singh Dhindsa, M.D.||IM-Endocrinology||“Hypogonadotropic hypogonadism in obese adolescents and young men”|
|Jianguo Liu, M.D., Ph.D.||IM-Infectious Diseases, Allergy & Immunology||“A new strategy for treating breast tumor by RNA-binding protein MCPIP1”|
|Nicola Pozzi, Ph.D.||Biochemistry and Molecular Biology||“Autoimmunity: Structural studies on the mechanisms of antigen-antibody recognition in the antiphospholipid syndrome”|
|Guangyong Peng, M.D., Ph.D.||IM-Infectious Diseases, Allergy & Immunology||“Reprogramming tumor metabolism and controlling the fate and function of tumor-specific T cells for tumor immunotherapy”|
|Amelia Pinto, Ph.D.||Molecular Microbiology and Immunology||“Identification of novel zika virus specific HLA-A*02 T cell epitopes”|
|Ryan Teague, Ph.D.||Molecular Microbiology and Immunology||“Obesity as an obstacle to cancer immunotherapy”|
|Alessandro Vindigni, Ph.D.||Biochemistry and Molecular Biology||“Redefining replication stress response pathways in BRCA1-deficient cells”|